Catherine M. Szyman - 13 Feb 2024 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Reporting relationship: CVP, Critical Care
Issuer ticker: EW
Reported as of: 13 Feb 2024
Net transaction value: -$2,313,604
SEC form: 4
Accepted by SEC: 15 Feb 2024, 17:25:32 UTC
Prior SEC filing: 10 Oct 2023
Next SEC filing: 23 Feb 2024
Source filing: View source filing
Reporting owner signature: Linda J. Park, Attorney-in-Fact

Key filing fact

Catherine M. Szyman filed Form 4 for Edwards Lifesciences Corp (EW) on 15 Feb 2024.

Key facts

This page summarizes Catherine M. Szyman's Form 4 filing for Edwards Lifesciences Corp (EW).
6 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 15 Feb 2024, 17:25.

Change

Previous filing in this sequence was filed on 10 Oct 2023.
Current net transaction value: -$2,313,604.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EW transaction

Common Stock

Options Exercise

Transaction value: $735,000
Shares: +20,000
Change %: +57%
Price: $36.75
Shares after: 54,814
Date: 13 Feb 2024
Ownership: Direct

EW transaction

Common Stock

Sale

Transaction value: $1,729,200
Shares: -20,000
Change %: -36%
Price: $86.46
Shares after: 34,814
Date: 13 Feb 2024
Ownership: Direct
Footnotes: F1

EW transaction

Common Stock

Options Exercise

Transaction value: $992,250
Shares: +27,000
Change %: +78%
Price: $36.75
Shares after: 61,814
Date: 15 Feb 2024
Ownership: Direct

EW transaction

Common Stock

Sale

Transaction value: $2,311,654
Shares: -27,000
Change %: -44%
Price: $85.62
Shares after: 34,814
Date: 15 Feb 2024
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EW transaction Derivative

Employee Stock Option (Right to Acquire)

Options Exercise

Transaction value: $0
Shares: -20,000
Change %: -43%
Price: $0.000000
Shares after: 27,000
Date: 13 Feb 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,000
Exercise price: $36.75

EW transaction Derivative

Employee Stock Option (Right to Acquire)

Options Exercise

Transaction value: $0
Shares: -27,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 15 Feb 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 27,000
Exercise price: $36.75

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This transaction was executed in multiple trades at prices ranging from $86.00 to $86.81. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Footnote F2

This transaction was executed in multiple trades at prices ranging from $85.44 to $85.83. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC remarks

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person